Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Compugen Ltd CGEN

Healthcare Biotechnology
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company... see more

Recent & Breaking News (NDAQ:CGEN)

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

PR Newswire January 8, 2024

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire January 8, 2024

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

PR Newswire December 19, 2023

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

PR Newswire December 19, 2023

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Business Wire December 19, 2023

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

PR Newswire November 6, 2023

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

PR Newswire November 3, 2023

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer

PR Newswire October 31, 2023

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023

PR Newswire October 24, 2023

Compugen to Present at Single Cell Genomics 2023 Meeting

PR Newswire October 3, 2023

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer

PR Newswire October 2, 2023

Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire August 31, 2023

Compugen Reports Second Quarter 2023 Results

PR Newswire August 7, 2023

Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

PR Newswire July 17, 2023

Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

PR Newswire June 22, 2023

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire June 13, 2023

Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer

PR Newswire June 5, 2023

Compugen Reports First Quarter 2023 Results

PR Newswire May 15, 2023

Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

PR Newswire May 11, 2023

Compugen to Present at the JMP Securities Life Sciences Conference

PR Newswire May 9, 2023